Form D · Biotechnology
Aether Therapeutics Inc.
Austin, TX · CIK 0002004745
Offering snapshot reported Jan 19, 2024 · SEC filing
- Reported sold
- $4.08M Offering amount: $6.58M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Jan 5, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 19, 2024 | Initial | $4,078,010 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-502978
The company has the right to raise an additional $2,502,856 but the offering shall not last more than one year.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Issuer Direct Sales Only | None |
Source: Form D, filed Jan 19, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John D Harris | Director, Executive |
| Eric K Olson | Director |
| Wolfgang Sadee | Director |
| Jon S Saxe | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4200 Marathon Boulevard Suite 200
Austin, TX, 78756
Austin, TX, 78756